Edition:
India

Titan Pharmaceuticals Inc (TTNP.OQ)

TTNP.OQ on NASDAQ Stock Exchange Capital Market

1.06USD
23 Feb 2018
Change (% chg)

$0.06 (+6.00%)
Prev Close
$1.00
Open
$1.06
Day's High
$1.06
Day's Low
$1.06
Volume
10,204
Avg. Vol
27,778
52-wk High
$3.95
52-wk Low
$0.95

Select another date:

Sat, Feb 3 2018

BRIEF-Titan Announces Amendment To Horizon Loan Agreement

* TITAN PHARMACEUTICALS INC - ENTRY INTO AN AMENDMENT TO JULY 2017 LOAN AGREEMENT WITH HORIZON TECHNOLOGY FINANCE CORPORATION

BRIEF-Titan Pharmaceuticals Says Co​ Entered Into A Binding Term Sheet With L. Molteni & C. Dei F.Lli Alitti Societ*I Esercizio

* TITAN PHARMACEUTICALS INC - ON NOV 27, CO​ ENTERED INTO A BINDING TERM SHEET WITH L. MOLTENI & C. DEI F.LLI ALITTI SOCIET*I ESERCIZIO - SEC FILING

BRIEF-Titan Pharmaceuticals Partners With Molteni To Market Probuphine In Europe

* TITAN PHARMACEUTICALS PARTNERS WITH MOLTENI TO MARKET PROBUPHINE® IN EUROPE

CORRECTED-BRIEF-European Medicines Agency Accepts Titan's Marketing Application For Probuphine

* EUROPEAN MEDICINES AGENCY ACCEPTS TITAN PHARMACEUTICALS' MARKETING AUTHORIZATION APPLICATION FOR PROBUPHINE®

BRIEF-Titan Pharmaceuticals reports Q3 loss per share of $0.20

* Titan pharmaceuticals reports third quarter 2017 financial results

BRIEF-Titan Pharmaceuticals files for offering of up to 280,612 shares by selling stockholder

* Titan Pharmaceuticals Inc files for offering of up to 280,612 shares of co's common stock by the selling stockholder - SEC filing‍​ Source text:[http://bit.ly/2izOUEZ] Further company coverage:

BRIEF-Titan Pharmaceuticals and Opiant Pharmaceuticals collaborate to explore a new approach to opioid use disorder treatment

* Titan Pharmaceuticals and Opiant Pharmaceuticals collaborate to explore a new approach to opioid use disorder treatment

BRIEF-Opiant Pharma, Titan Pharmac to explore new treatments for opioid abuse

* Opiant Pharmaceuticals and Titan Pharmaceuticals collaborate to explore a new approach to opioid use disorder treatment

BRIEF-Titan Pharma receives FDA clearance to begin clinical study of Parkinson's disease treatment

* Titan Pharmaceuticals receives fda clearance to begin clinical study of Parkinson's disease treatment Source text for Eikon: Further company coverage:

Select another date: